By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex reported after the close of the market Thursday that its first-quarter revenues increased 30 percent, with a particularly strong quarter for its assay sales.

The Austin, Texas-based multiplex diagnostics and research products firm brought in total revenues of $33.3 million for the three-month period ended March 31, compared to $25.6 million for the first quarter of 2009. The firm beat analysts' consensus estimate for revenue of $32.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.